Literature DB >> 7986008

Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells.

D L Taylor1, M S Kang, T M Brennan, C G Bridges, P S Sunkara, A S Tyms.   

Abstract

The 6-O-butanoyl derivative of castanospermine (MDL 28,574) was previously shown to be approximately 30-fold more potent than the naturally occurring molecule at inhibiting the replication of human immunodeficiency virus (HIV) (D. L. Taylor, P. S. Sunkara, P. S. Liu, M. S. Kang, T. L. Bowlin, and A. S. Tyms, AIDS 5:693-698, 1991). We now report that consistent with its improved anti-HIV activity, MDL 28,574 is more effective (50% inhibitory concentration [IC50], 20 microM) than the parent molecule (IC50, 254 microM) at causing the accumulation of glucosylated oligosaccharides in HIV-infected cells by inhibition of glycoprotein processing. These were predominantly of the glucose 3 type, as determined by P4 Bio-Gel analysis after digestion with purified alpha-glucosidase I, indicating that, intracellularly, this enzyme is the major target for inhibition. MDL 28,574, however, was less active (IC50, 1.27 microM) than castanospermine (IC50, 0.12 microM) against the mutual target enzyme, cellular alpha-glucosidase I, in a cell-free assay system. The increased effects of MDL 28,574 against alpha-glucosidase I in cell culture were attributed to the improved cellular uptake of the more lipophilic derivative. Inhibition of this enzyme activity in HIV-infected H9 cells impaired viral glycoprotein processing and resulted in the expression of abnormally configured gp120. This did not affect virus production, but the virions had decreased infectivity which was partially related to a reduced ability to bind to CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986008      PMCID: PMC284636          DOI: 10.1128/AAC.38.8.1780

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.

Authors:  B D Walker; M Kowalski; W C Goh; K Kozarsky; M Krieger; C Rosen; L Rohrschneider; W A Haseltine; J Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

Authors:  J S McDougal; J K Nicholson; G D Cross; S P Cort; M S Kennedy; A C Mawle
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

3.  Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4.

Authors:  A Peterson; B Seed
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

4.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.

Authors:  W R Gallaher
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

Review 5.  Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains.

Authors:  A D Elbein
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

6.  Purification and characterization of glucosidase I involved in N-linked glycoprotein processing in bovine mammary gland.

Authors:  K Shailubhai; M A Pratta; I K Vijay
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

7.  Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.

Authors:  H Geyer; C Holschbach; G Hunsmann; J Schneider
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

8.  Inhibition of HIV replication by amino-sugar derivatives.

Authors:  G W Fleet; A Karpas; R A Dwek; L E Fellows; A S Tyms; S Petursson; S K Namgoong; N G Ramsden; P W Smith; J C Son
Journal:  FEBS Lett       Date:  1988-09-12       Impact factor: 4.124

9.  Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.

Authors:  R A Gruters; J J Neefjes; M Tersmette; R E de Goede; A Tulp; H G Huisman; F Miedema; H L Ploegh
Journal:  Nature       Date:  1987 Nov 5-11       Impact factor: 49.962

10.  Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport.

Authors:  M J Gething; K McCammon; J Sambrook
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

View more
  9 in total

1.  Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo.

Authors:  Kevin Whitby; Theodore C Pierson; Brian Geiss; Kelly Lane; Michael Engle; Yi Zhou; Robert W Doms; Michael S Diamond
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.

Authors:  Xuesen Zhao; Fang Guo; Mary Ann Comunale; Anand Mehta; Mohit Sehgal; Pooja Jain; Andrea Cuconati; Hanxin Lin; Timothy M Block; Jinhong Chang; Ju-Tao Guo
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.

Authors:  Pamela A Norton; Stephan Menne; Gomathinayagam Sinnathamby; Lucy Betesh; Paul J Cote; Ramila Philip; Anand S Mehta; Bud C Tennant; Timothy M Block
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

4.  The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

Authors:  P B Fischer; M Collin; G B Karlsson; W James; T D Butters; S J Davis; S Gordon; R A Dwek; F M Platt
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.

Authors:  P B Fischer; G B Karlsson; T D Butters; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure.

Authors:  P B Fischer; G B Karlsson; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 7.  Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents.

Authors:  Jinhong Chang; Ju-Tao Guo; Yanming Du; Timothy Block
Journal:  Emerg Microbes Infect       Date:  2013-11-20       Impact factor: 7.163

8.  Castanospermine reduces Zika virus infection-associated seizure by inhibiting both the viral load and inflammation in mouse models.

Authors:  Anil M Tharappel; Yichen Cheng; Eric H Holmes; Gary K Ostrander; Hengli Tang
Journal:  Antiviral Res       Date:  2020-09-16       Impact factor: 5.970

Review 9.  Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions.

Authors:  Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2013-06-29       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.